What is the price of Arovella Therapeutics Limited (ALA)

The price of Arovella Therapeutics Limited (ALA) is $0.04584351

What is the market cap of Arovella Therapeutics Limited (ALA)

The market cap of Arovella Therapeutics Limited (ALA) is $55.42M

Arovella Therapeutics Limited (ALA) Revenue

Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally. Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers. Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment. Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London. Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.

Year	Revenue	Change
Not enough data for the provided dates.

Year

Revenue

Change

Not enough data for the provided dates.

Company	Revenue	Revenue Difference	Country
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	$2.23B	-	US

Company

Revenue

Revenue Difference

Country